Drug
ABBV-8E12
ABBV-8E12 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
3
60%
Ph phase_1
1
20%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(2)
Other(1)
Detailed Status
Terminated2
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
terminated240%
completed240%
unknown120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
NCT02880956
terminatedphase_2
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
NCT02985879
terminatedphase_2
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
NCT03391765
completedphase_1
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
NCT03413319
unknown
Expanded Access to ABBV-8E12
NCT03744546
Clinical Trials (5)
Showing 5 of 5 trials
NCT02880956Phase 2
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
NCT02985879Phase 2
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
NCT03391765Phase 2
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
NCT03413319Phase 1
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
NCT03744546
Expanded Access to ABBV-8E12
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5